News

Positive results with signs of efficacy

Read the KL1333 news hereRead more in the Newsletter
Latest news

News
About us

Abliva
Investor relations

General meeting
Development

Primary mitochondrial diseases

Primary mitochondrial diseases are metabolic diseases that affect the cells’ abili to convert energy. The disorders can manifest differently depending on the organs affected and have historically been viewed as clinical syndromes,
Investor relations

Investors

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company is focused on two projects.
Our team
Events and Presentations
Contact
Our partners and advisers
General meeting
Financial Calendar
Event

Redeye Investor Forum Online

Abliva participated at the Redeye Investor Forum Online, on 20 May 2021. CEO Ellen Donnelly presented the company as well as new data from the KL1333 Phase 1a/b study.

See the presentation here
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all